Zhejiang Jolly Pharmaceutical (300181.SZ) has obtained the registration certificate for its Polycarbophil Calcium Granules drug.
Zhuhai Rongxin Pharmaceutical Co., Ltd. (300181.SZ) announced that the company has received the "Drug Registration Certificate" for the Polycarbophil Calcium Granules issued by the National Medical Products Administration. Polycarbophil calcium is a water-absorbent polymer that de-calcifies in the acidic state of the stomach, converting to polycarbophil, absorbing water and expanding in the small and large intestines, exerting pharmacological effects, thereby improving symptoms of constipation. The approved indication for the Polycarbophil Calcium Granules this time is "relief of constipation symptoms in patients with irritable bowel syndrome (constipation type)", adding a granule dosage form to the company's existing polycarbophil calcium tablets, forming a good complement. Granules are convenient for patients with difficulty swallowing or a preference for different dosage forms, especially suitable for elderly and pediatric patients, further meeting the diverse needs of clinical medication.
Zhejiang Jolly Pharmaceutical (300181.SZ) announced that the company has received the "Drug Registration Certificate" for the polyethylene glycol calcium granules issued by the National Medical Products Administration. Polyethylene glycol calcium is a water-absorbing high molecular polymer that decalcifies in the acidic state of the stomach, converting to polyethylene glycol, absorbing water and expanding in the small and large intestines, exerting pharmacological effects, and improving constipation symptoms. The approved polyethylene glycol calcium granules this time are indicated for "relieving constipation symptoms in patients with irritable bowel syndrome (constipation type)". This granular dosage form is a new addition for the company in this category, complementing the company's existing polyethylene glycol calcium tablets. Granular dosage forms are easy for patients with difficulty swallowing or who prefer different dosage forms to use, especially suitable for the elderly and pediatric patient groups, further meeting the diversified needs of clinical drug use.
Related Articles
SHANDONG XINHUA (00719): Notification of approval for drug supplement application obtained for Zhe Maibu
Jiangsu Hengrui Pharmaceuticals (01276): SHR-1819 injection, SHR-1905 injection obtained drug clinical trial approval letter.
MIN XIN HOLD (00222) announces profit growth, with estimated annual net profit attributable to shareholders of approximately HK$1.1 billion to HK$1.3 billion, a year-on-year increase of about 25% to 48%.
SHANDONG XINHUA (00719): Notification of approval for drug supplement application obtained for Zhe Maibu
Jiangsu Hengrui Pharmaceuticals (01276): SHR-1819 injection, SHR-1905 injection obtained drug clinical trial approval letter.
MIN XIN HOLD (00222) announces profit growth, with estimated annual net profit attributable to shareholders of approximately HK$1.1 billion to HK$1.3 billion, a year-on-year increase of about 25% to 48%.
